Inhibikase Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Inhibikase Therapeutics
IKT Stock  USD 1.69  0.00  0.00%   
Analyzing historical trends in various income statement and balance sheet accounts from Inhibikase Therapeutics' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Inhibikase Therapeutics' valuation are summarized below:
Gross Profit
-27.2 M
Market Capitalization
119.2 M
Enterprise Value Revenue
2.748
Revenue
1
Earnings Share
(0.04)
There are currently one hundred twenty fundamental trends for Inhibikase Therapeutics that can be evaluated and compared over time across competitors. All traders should confirm Inhibikase Therapeutics' regular fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 213 M in 2026. Enterprise Value is likely to gain to about 204.1 M in 2026

Inhibikase Therapeutics Total Revenue

0.0

Check Inhibikase Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inhibikase Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 28.7 K, Interest Expense of 89.9 K or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 28.41, Dividend Yield of 0.0 or PTB Ratio of 2.25. Inhibikase financial statements analysis is a perfect complement when working with Inhibikase Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Inhibikase Stock
Check out the analysis of Inhibikase Therapeutics Correlation against competitors.
For more information on how to buy Inhibikase Stock please use our How to Invest in Inhibikase Therapeutics guide.

Inhibikase Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets119.1 M113.4 M25.4 M
Slightly volatile
Short and Long Term Debt Total94.5 K99.5 K306.8 K
Slightly volatile
Other Current Liabilities2 M3.1 M1.5 M
Slightly volatile
Total Current Liabilities3.8 M4.3 M2.8 M
Slightly volatile
Accounts Payable1 M1.1 M763.6 K
Slightly volatile
Cash68.2 M65 M15.4 M
Slightly volatile
Other Assets1.091.15276.7 K
Very volatile
Cash And Short Term Investments117.8 M112.2 M24.6 M
Slightly volatile
Common Stock Shares Outstanding83.8 M79.8 M15.4 M
Slightly volatile
Liabilities And Stockholders Equity119.1 M113.4 M25.4 M
Slightly volatile
Other Current Assets597.3 K1 M384.5 K
Slightly volatile
Other Stockholder Equity228.5 M217.6 M53.5 M
Slightly volatile
Total Liabilities3.9 M4.3 M2.9 M
Slightly volatile
Total Current Assets118.9 M113.2 M25.2 M
Slightly volatile
Short Term Debt195.6 K99.5 K262.9 K
Slightly volatile
Common Stock83.8 K79.8 K22.8 K
Slightly volatile
Current Deferred Revenue2.8 M2.7 M1.1 M
Slightly volatile
Common Stock Total Equity8.599.054.8 K
Slightly volatile
Deferred Long Term Liabilities2.5 K2.6 K845.6 K
Slightly volatile
Short and Long Term Debt124.7 K224 K211.1 K
Pretty Stable
Capital Stock83.8 K79.8 K22.4 K
Slightly volatile
Long Term Debt303.5 K317.9 K279.9 K
Slightly volatile

Inhibikase Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization28.7 K30.2 K1.8 M
Pretty Stable
Other Operating Expenses34.5 M32.9 M10.2 M
Slightly volatile
Research Development20.8 M19.8 M6.4 M
Slightly volatile
Cost Of Revenue28.7 K30.2 K2.3 M
Pretty Stable
Total Operating Expenses34.5 M32.8 M9 M
Slightly volatile
Selling General Administrative13.7 M13.1 M5.1 M
Slightly volatile
Interest Income746.1 K1.2 M288.5 K
Slightly volatile

Inhibikase Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation9.8 M9.4 M2.1 M
Slightly volatile
Begin Period Cash Flow8.7 M10.5 M5.4 M
Slightly volatile
Other Non Cash Items175.2 K184.4 K425 K
Pretty Stable
End Period Cash Flow68.2 M65 M15.4 M
Slightly volatile
Change To Netincome1.6 M2.6 M1.3 M
Slightly volatile
Issuance Of Capital Stock124.9 M119 M25.4 M
Slightly volatile
Dividends Paid62.1 K69.9 K76.3 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio28.4129.961.1255
Slightly volatile
Days Sales Outstanding11110650.6829
Slightly volatile
Average Payables822.7 K1 M855.1 K
Slightly volatile
Stock Based Compensation To Revenue0.891.730.9009
Slightly volatile
Capex To Depreciation0.08770.092327.689
Slightly volatile
Payables Turnover0.02380.02513.3611
Pretty Stable
Sales General And Administrative To Revenue0.50.560.6117
Slightly volatile
Research And Ddevelopement To Revenue49.447.0518.4469
Slightly volatile
Capex To Revenue0.05970.06291.5206
Slightly volatile
Cash Per Share1.21.271.9984
Slightly volatile
Days Payables Outstanding6.8 K11.8 K5.7 K
Slightly volatile
Net Debt To EBITDA1.941.850.6585
Slightly volatile
Current Ratio24.9223.735.8936
Slightly volatile
Receivables Turnover3.383.5613.0517
Slightly volatile
Capex Per Share0.00290.00310.0449
Slightly volatile
Average Receivables21.8 K22.9 K199.6 K
Slightly volatile
Revenue Per Share0.05340.05620.6919
Slightly volatile
Interest Debt Per Share0.00170.00180.1758
Slightly volatile
Debt To Assets0.00120.00131.511
Slightly volatile
Operating Cycle11110650.6829
Slightly volatile
Days Of Payables Outstanding6.8 K11.8 K5.7 K
Slightly volatile
Ebt Per Ebit1.11.111.0235
Very volatile
Quick Ratio24.9223.735.8936
Slightly volatile
Cash Ratio14.313.623.5789
Slightly volatile
Days Of Sales Outstanding11110650.6829
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.151.0261
Slightly volatile
Fixed Asset Turnover0.440.790.3431
Slightly volatile
Debt Ratio0.00120.00131.511
Slightly volatile
Price Sales Ratio28.4129.961.1255
Slightly volatile
Asset Turnover0.01960.02074.6918
Slightly volatile

Inhibikase Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap213 M202.9 M92.6 M
Slightly volatile

Inhibikase Fundamental Market Drivers

Inhibikase Upcoming Events

29th of March 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
29th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Inhibikase Therapeutics Financial Statements

Inhibikase Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Inhibikase Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Inhibikase Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Inhibikase Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue2.7 M2.8 M
Cost Of Revenue30.2 K28.7 K
Stock Based Compensation To Revenue 1.73  0.89 
Sales General And Administrative To Revenue 0.56  0.50 
Research And Ddevelopement To Revenue 47.05  49.40 
Capex To Revenue 0.06  0.06 
Revenue Per Share 0.06  0.05 
Ebit Per Revenue(88.69)(84.25)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Inhibikase Stock Analysis

When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY